Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Eberhard-Karls University, Tübingen, Germany.
Inflammation. 2014 Aug;37(4):1102-10. doi: 10.1007/s10753-014-9834-0.
The hallmarks of acute lung injury (ALI) are the compromised alveolar-capillary barrier and the extravasation of leukocytes into the alveolar space. Given the fact that the peroxisome proliferator-activated receptor-γ agonist rosiglitazone holds significant anti-inflammatory properties, we aimed to evaluate whether rosiglitazone could dampen these hallmarks of local pulmonary inflammation in a porcine model of lung injury. For this purpose, we used a model of lipopolysaccharide (LPS, 50 μg/kg)-induced ALI. One hundred twenty minutes following the infusion of LPS, we started the exposure to rosiglitazone through inhalation or infusion. We found that intravenous rosiglitazone significantly controlled local pulmonary inflammation as determined through the expression of cytokines within the alveolar compartment. Furthermore, we found a significant reduction of the protein concentration and neutrophil activity within the alveolar space. In summary, we therefore conclude that the treatment with rosiglitazone might dampen local pulmonary inflammation during the initial stages of ALI.
急性肺损伤 (ALI) 的特征是肺泡毛细血管屏障受损和白细胞渗出到肺泡腔。鉴于过氧化物酶体增殖物激活受体-γ 激动剂罗格列酮具有显著的抗炎特性，我们旨在评估罗格列酮是否可以减轻猪肺损伤模型中局部肺部炎症的这些特征。为此，我们使用了脂多糖 (LPS，50μg/kg) 诱导的 ALI 模型。在 LPS 输注 120 分钟后，我们开始通过吸入或输注暴露于罗格列酮。我们发现静脉内罗格列酮通过肺泡腔内细胞因子的表达显著控制局部肺部炎症。此外，我们发现肺泡腔内的蛋白质浓度和中性粒细胞活性显著降低。总之，我们因此得出结论，在 ALI 的初始阶段，罗格列酮的治疗可能会抑制局部肺部炎症。
